With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News

FDA OKs Drug to Treat Neurologic Symptoms in Hunter Syndrome

The U.S. Food and Drug Administration has approved Denali Therapeutics' therapy to treat children ⁠with a rare genetic disorder, marking the first regulatory green light for...

FDA Seeks New Warning for Certain Parkinson's Drugs

The FDA said on Friday it has notified manufacturers of certain Parkinson's ⁠disease treatments to update their prescribing information with a...

Scottish Lawmakers Vote Against Allowing Assisted Dying

Scottish lawmakers have voted against legalising assisted, crushing hopes for a historic law change, ⁠as similar proposals in England and Wales also look set to fail.

Little Evidence of Cannabis Efficacy for Psychiatric Illness

A new review shows insufficient or low-quality evidence to suggest cannabinoids are effective at treating most psychiatric conditions and substance use disorders.

Prenatal Antiseizure Med Exposure: Risks Vary by Agent

A large cohort study sheds new light on neurodevelopmental risk in children after prenatal antiseizure medication exposure, with variation across individual agents.

Anxiety and Depression May Raise Risk for Aneurysm Rupture

Anxiety and depression are linked to an increased risk for rupture and mortality in patients with unruptured intracranial aneurysms, a new cohort study shows.

Todays Updates

Do Anatomy Atlases Reflect Social Inequalities?

Historical anatomical illustrations reflect social inequality and may require an ethical context to guide their continued use in clinical education and surgical reference.

MRD-Guided Azacitidine May Delay Relapse in AML, MDS

New data highlight the activity and safety of MRD-guided preemptive azacitidine in patients with myelodysplastic neoplasms or AML who develop MRD positivity.

HER3 Antibody Drug Conjugate Shows Promise in NSCLC

Researchers examine overall response rates of a HER3-targeting antibody-drug conjugate in pretreated patients with non-small cell lung cancer.

Todays Updates

Do Anatomy Atlases Reflect Social Inequalities?

Historical anatomical illustrations reflect social inequality and may require an ethical context to guide their continued use in clinical education and surgical reference.

MRD-Guided Azacitidine May Delay Relapse in AML, MDS

New data highlight the activity and safety of MRD-guided preemptive azacitidine in patients with myelodysplastic neoplasms or AML who develop MRD positivity.

HER3 Antibody Drug Conjugate Shows Promise in NSCLC

Researchers examine overall response rates of a HER3-targeting antibody-drug conjugate in pretreated patients with non-small cell lung cancer.

Latest News

The U.S. Food and Drug Administration has approved Denali Therapeutics' therapy to treat children ⁠with a rare genetic disorder, marking the first regulatory green light for...

The FDA said on Friday it has notified manufacturers of certain Parkinson's ⁠disease treatments to update their prescribing information with a...

Scottish lawmakers have voted against legalising assisted, crushing hopes for a historic law change, ⁠as similar proposals in England and Wales also look set to fail.

A new review shows insufficient or low-quality evidence to suggest cannabinoids are effective at treating most psychiatric conditions and substance use disorders.

A large cohort study sheds new light on neurodevelopmental risk in children after prenatal antiseizure medication exposure, with variation across individual agents.

Anxiety and depression are linked to an increased risk for rupture and mortality in patients with unruptured intracranial aneurysms, a new cohort study shows.

News All Time

Positive Topline Results for Efgartigimod in Ocular MG

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

Smoking + Parkinson's: Lower Disease Risk, Higher Mortality

A large nationwide study revisits the smoking-Parkinson's paradox, linking current smoking to lower disease risk but linking quitting to lower all-cause mortality.

Stem Cell Therapy Safe, Feasible in Spina Bifida

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal myelomeningocele repair.

Does Caring for Grandchildren Slow Cognitive Decline?

Grandmothers who care for grandchildren show slower cognitive decline over time than non-caregivers do.

Teen Cannabis Use Tied to Increase in Serious Mental Illness

A new study shows that teens with past-year cannabis use are twice as likely to be diagnosed with psychotic or bipolar disorders within 2 years of first use.

Fertility Treatments Linked to Higher Med Use in Offspring

Children conceived through medically assisted reproduction have higher out-of-hospital healthcare utilization including mental health medications.

Lifetime Risk Estimates for Dementia, MCI: New Data

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Fibromyalgia-PTSD Link Shows Bidirectional Relationship

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

Redefining Cognitive Assessment With One Blood Test

Blood p-tau217 testing in real-world practice enhances diagnostic accuracy and neurologists' diagnostic confidence, with the greatest diagnostic shifts seen in mild cognitive impairment and dementia.

Trials Offer Mixed Results on BTK Potential for PPMS

Promising findings for fenebrutinib and disappointing results for tolebrutinib offer mixed results on the potential of BTK inhibitors for primary progressive MS.

Wrist-Worn Sleep Trackers Predict Depression Relapse

Actigraphy data show irregular sleep-wake rhythms nearly double the risk for relapse in individuals with remitted major depressive disorder.

What If We’ve Been Wrong About How ADHD Drugs Work?

A new analysis of brain scans from nearly 12,000 children could change the way clinicians and researchers think about how stimulants for ADHD work.

Vertebral Fractures Tied to Lower Lung Volumes in ILD

Thoracic vertebral fractures may worsen lung function and reduce lung volumes in patients with interstitial lung disease.

Japan Endorses IPS-derived Treatment for Parkinson's

A panel of specialists has endorsed an iPS cell-derived treatment for Parkinson's ⁠disease, paving the ‌way for the world's first medical products based on the technology.

Cognitive Training May Lower Dementia Risk 20 Years Later

In a long-running RCT, older adults who completed adaptive speed-of-processing training with boosters were less likely to develop dementia — a benefit not seen with memory or reasoning training.

Lifelong Cognitive Enrichment Tied to Lower Dementia Risk

Lifelong cognitive enrichment is linked to a lower risk for Alzheimer's disease, delayed onset, and better cognitive function despite brain pathology.

Recommended News For You

Cancer and HIV Vaccines Enter the Therapeutic Era

ALK-positive lung cancer trial results show unprecedented progression-free survival.

In advanced endometrial cancer, immunocheckpoint inhibitor-chemotherapy combination improves overall survival.

Cancer screening rates down among American adults

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients

Advanced imaging, targeted therapy help men with prostate cancer safely defer surgery and radiation therapy

Recommended Articles For You

New Frontiers in Diagnosing and Managing Myelodysplastic Syndromes (MASLD) 

The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond 

Liquid Biopsies and ctDNA: Transforming Cancer Detection, Monitoring, and Clinical Decisions 

Optimizing Chemotherapy Dosing: From Phase 1 Dose Escalation to Modification 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

What Kate Middleton Reminds Us About the Role of Privacy in Healing.

2.

Cancer patients rarely use ancestry testing.

3.

Photoacoustic spectral analysis for gaining knowledge of the tumor microenvironment.

4.

Having a tattoo could increase your risk of developing lymphoma.

5.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

1.

Exploring the Mysteries of Myxoma: A New Frontier in Medical Research

2.

Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning 

3.

Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment

4.

Revolutionizing Cancer Care: The Promise of Early Detection and Biomarkers

5.

Liquid Biopsy: A Revolutionary Tool for Early Detection and Monitoring of Colorectal Cancer

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

2.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

3.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I

4.

Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot